| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,315 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
500,000 |
525,000 |
525,000 |
525,000 |
| Total Buy Value |
$324,050 |
$343,050 |
$343,050 |
$343,050 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
See Remarks |
• • – |
2024-04-05 |
4 |
A |
$0.50 |
$16,349 |
D/D |
32,697 |
1,335,325 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2024-03-22 |
4 |
A |
$0.55 |
$14,940 |
D/D |
27,163 |
1,302,628 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2024-03-08 |
4 |
A |
$0.67 |
$14,831 |
D/D |
22,136 |
1,275,465 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2024-02-23 |
4 |
A |
$0.68 |
$14,834 |
D/D |
21,815 |
1,253,329 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2024-02-15 |
4 |
B |
$0.65 |
$324,050 |
I/I |
500,000 |
625,969 |
0.01 |
-32% |
|
| Armen Garo H |
See Remarks |
• • – |
2024-02-09 |
4 |
A |
$0.75 |
$14,834 |
D/D |
19,778 |
1,231,514 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2024-01-26 |
4 |
A |
$0.66 |
$14,834 |
D/D |
22,475 |
1,211,736 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2024-01-12 |
4 |
A |
$0.64 |
$14,833 |
D/D |
23,177 |
1,439,261 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2023-12-29 |
4 |
A |
$0.83 |
$19,466 |
D/D |
23,453 |
1,416,084 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2023-12-15 |
4 |
A |
$0.69 |
$16,183 |
D/D |
23,453 |
1,396,538 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2023-12-01 |
4 |
A |
$0.78 |
$16,167 |
D/D |
20,727 |
1,373,085 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2023-11-17 |
4 |
A |
$0.69 |
$16,223 |
D/D |
23,511 |
1,352,358 |
|
- |
|
| Wiinberg Ulf |
|
– • – |
2023-11-15 |
4 |
B |
$0.76 |
$19,000 |
D/D |
25,000 |
124,063 |
0.01 |
-25% |
|
| Armen Garo H |
See Remarks |
• • – |
2023-11-03 |
4 |
A |
$0.84 |
$16,128 |
D/D |
19,200 |
1,328,847 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2023-10-20 |
4 |
A |
$0.89 |
$16,146 |
D/D |
18,142 |
1,309,647 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2023-10-06 |
4 |
A |
$1.06 |
$16,223 |
D/D |
15,305 |
1,291,505 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2023-09-22 |
4 |
A |
$1.18 |
$16,388 |
D/D |
13,888 |
1,276,200 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2023-09-08 |
4 |
A |
$1.23 |
$16,168 |
D/D |
13,145 |
1,262,312 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2023-01-05 |
4 |
A |
$2.45 |
$591,388 |
D/D |
241,383 |
1,249,167 |
|
- |
|
| Oday Steven J |
Chief Medical Officer |
• – – |
2023-01-05 |
4 |
A |
$2.45 |
$267,983 |
D/D |
109,381 |
272,384 |
|
- |
|
| Klaskin Christine M |
PFO & PAO |
• – – |
2023-01-05 |
4 |
A |
$2.45 |
$76,670 |
D/D |
31,294 |
153,937 |
|
- |
|
| Hirsch Susan B |
Director |
– • – |
2023-01-03 |
4 |
A |
$2.59 |
$18,749 |
D/D |
7,239 |
108,725 |
|
- |
|
| Hirsch Susan B |
Director |
– • – |
2022-10-03 |
4 |
A |
$2.60 |
$18,747 |
D/D |
7,216 |
101,486 |
|
- |
|
| Hirsch Susan B |
Director |
– • – |
2022-07-01 |
4 |
A |
$1.85 |
$18,755 |
D/D |
10,138 |
94,270 |
|
- |
|
| Hirsch Susan B |
Director |
– • – |
2022-04-01 |
4 |
A |
$2.75 |
$18,751 |
D/D |
6,811 |
28,382 |
|
- |
|
185 Records found
|
|
Page 1 of 8 |
|
|
